Telix adds two non-executive directors to board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Nasdaq notches record high close as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
- Citi cuts investment banking analyst program to two years - Bloomberg
- Alaska LNG shipping savings justifies billions in investment, developer says
- Paramount Skydance to close WBD deal, change ticker to SKYD
- Nasdaq notches record high close as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
Telix Strengthens Board with Additional Director Appointments
April 8, 2026 6:44 PM EDTMELBOURNE, Australia and INDIANAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix) today announces two additional Non-Executive Director (NED) appointments, effective May 11, 20261, as part of Board expansion and succession planning:
Maria Rivas, MD is an experienced public company board director and S&P 100 senior pharmaceutical executive with more than 25 years experience in late-stage clinical development, commercialization and governance leadership. Dr. Rivas currently serves on the board of directors of The Cooper Companies, Inc. (NASDAQ: COO), a medical technology... More


